Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Depreciation & Amortization (IS): 2021-2025

Historic Depreciation & Amortization (IS) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $338,000.

  • Xeris Biopharma Holdings' Depreciation & Amortization (IS) rose 10.10% to $338,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 1.41%. This contributed to the annual value of $1.2 million for FY2024, which is 18.20% down from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Depreciation & Amortization (IS) is $338,000, which was up 4.00% from $325,000 recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Depreciation & Amortization (IS) peaked at $391,000 during Q3 2023, and registered a low of $281,000 during Q2 2024.
  • Moreover, its 3-year median value for Depreciation & Amortization (IS) was $326,000 (2024), whereas its average is $336,818.
  • Its Depreciation & Amortization (IS) has fluctuated over the past 5 years, first declined by 27.20% in 2024, then climbed by 15.66% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Depreciation & Amortization (IS) (Quarterly) stood at $349,000 in 2021, then increased by 5.16% to $367,000 in 2022, then decreased by 2.18% to $359,000 in 2023, then fell by 12.81% to $313,000 in 2024, then grew by 10.10% to $338,000 in 2025.
  • Its last three reported values are $338,000 in Q3 2025, $325,000 for Q2 2025, and $315,000 during Q1 2025.